Related Experiment Videos
Soluble MICA in malignant diseases.
Stefan Holdenrieder1, Petra Stieber, Andrea Peterfi
1Institute of Clinical Chemistry, University Hospital of Munich-Grosshadern, Ludwig-Maximilians-University, Munich, Germany. Stefan.Holdenrieder@med.uni-muenchen.de
International Journal of Cancer
|August 12, 2005
Summary
Soluble MICA (sMICA) levels are significantly elevated in cancer patients, correlating with disease stage and metastasis. This suggests sMICA may serve as a valuable biomarker for cancer diagnosis and staging.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- NKG2D receptor activation is crucial for natural killer and CD8 T cell responses.
- MICA, a ligand for NKG2D, is expressed on malignant cells and its release can impair anti-tumor immunity.
- Soluble MICA (sMICA) shedding is a proposed immune evasion strategy in cancer.
Purpose of the Study:
- To investigate the potential of soluble MICA (sMICA) as a diagnostic and staging biomarker in cancer.
- To analyze sMICA levels in individuals with malignancies, benign diseases, and healthy controls.
Main Methods:
- Serum samples from 512 individuals were analyzed for sMICA levels.
- Statistical analysis was performed to compare sMICA levels across different groups and correlate with clinical parameters.
Main Results:
- Significantly higher sMICA levels were observed in patients with various malignancies (median 161 pg/ml) compared to healthy individuals (median <30 pg/ml).
- Patients with benign diseases showed intermediate sMICA levels (median 84 pg/ml).
- Elevated sMICA levels in cancer patients correlated significantly with advanced cancer stage and presence of metastasis.
Conclusions:
- Serum sMICA levels are significantly elevated in cancer patients.
- sMICA shows potential as a biomarker for cancer diagnosis and staging.
- sMICA determination may offer additional insights into cancer progression and immune status.